Caliway Biopharmaceuticals Co. L
6919
株式のランク
#4340
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
株価
$2.29
時価総額
$3.56B
変化（1日）
-2.50%
変化（1年）
-57.22%
国
TW
取引 Caliway Biopharmaceuticals Co. L (6919)
カテゴリー
Healthcare
Caliway Biopharmaceuticals Co. L（6919）の株価履歴
終値の最高値: $2.44 （2026-10-01）
終値の最安値: $0.20 （2022-12-01）
終値の最安値: $0.20 （2022-12-01）
Caliway Biopharmaceuticals Co. L の株価履歴（2022 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -25.32% |
| 2025 | 190.26% |
| 2024 | 181.33% |
| 2023 | 210.73% |
| 2022 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $531.67 | 24.68% |
US
|
|
| $237.10 | 783.04% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $895.07 | 9.94% |
NL
|
|
| $288.17 | 1.24% |
BE
|
